In conjunction with Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., we are sharply focused on our ongoing global development program for our novel powder for oral solution formulation of crofelemer for rare intestinal failure indications in adults and pediatrics, including microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).

We are dedicated to supporting sustainability and local communities as we develop first-in-class, plant-based prescription medicines to address unmet medical needs for people globally.

Our product portfolio addresses multiple indications for gastrointestinal (GI) diseases, spanning multiple stages of development from preclinical to commercial approval.